Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Capital Expenditures (2017 - 2025)

Arcus Biosciences has reported Capital Expenditures over the past 9 years, most recently at $1.0 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $1.0 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $2.0 million (down 66.67% YoY), and the annual figure for FY2025 was $2.0 million, down 66.67%.
  • Capital Expenditures for Q4 2025 was $1.0 million at Arcus Biosciences, roughly flat from $1.0 million in the prior quarter.
  • Over the last five years, Capital Expenditures for RCUS hit a ceiling of $21.4 million in Q4 2021 and a floor of -$3.0 million in Q3 2022.
  • Median Capital Expenditures over the past 5 years was $1.9 million (2021), compared with a mean of $3.6 million.
  • Peak annual rise in Capital Expenditures hit 4510.99% in 2021, while the deepest fall reached 275.82% in 2021.
  • Arcus Biosciences' Capital Expenditures stood at $21.4 million in 2021, then crashed by 76.63% to $5.0 million in 2022, then skyrocketed by 260.0% to $18.0 million in 2023, then tumbled by 94.44% to $1.0 million in 2024, then changed by 0.0% to $1.0 million in 2025.
  • The last three reported values for Capital Expenditures were $1.0 million (Q4 2025), $1.0 million (Q1 2025), and $1.0 million (Q4 2024) per Business Quant data.